Selecta Biosciences Inc
SELB
Get informed when a big investor buys or sells
+ FollowMarket Cap$135.2M
Close$
Share Statistics
| Market cap | $135.20 Million |
|---|---|
| Enterprise Value | $-1,403,246.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.02 |
| Beta | 0.83 |
| Outstanding Shares | 29,467,130 |
Return
| Return on Equity | 121.29% |
|---|---|
| Return on Assets | -47.67% |
| Return on Invested Capital | 12.89% |
Valuation & Multiples
| P/E Ratio | -0.15 |
|---|---|
| PEG | 20.49 |
| Price to Sales | - |
| Price to Book Ratio | -0.18 |
| Enterprise Value to Revenue | -0.95 |
| Enterprise Value to EBIT | -0.04 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -7.84 |
| Debt to Equity | -0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$179,670
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Selecta Biosciences Inc
44 employees
CEO: Carsten Brunn Selecta Biosciences Inc. is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic protei...